Brief Summary
This trial aims to determine whether NOX66 (idronoxil) can be safely given in combination with nivolumab (an immune checkpoint inhibitor) and to determine the highest dosethe amount of medication taken of NOX66 that can be administered safely.
Intervention/Treatment
- Drug: NOX66
- Drug: Nivolumab
Inclusion Criteria
- Adult patients with histologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of solid metastatic tumours that are potentially amenable to treatment with nivolumab.
- Measurable disease by CT/MRI imagingtests that create detailed images of areas inside the body according to iRECIST and RECIST v1.1.
- Patients must have minor disease progression following at least 8 weeks of treatment with a specific checkpoint inhibitor or minor progression whilst on treatment with either chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells or a targeted therapymedication that targets specific molecular features of cancer cells.
- Adequate hepatic, renal and marrow function.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0–2
- Anticipated life-expectancy of at least 6 months.